Topical spironolactone is unlikely to change persistent adult acne care yet because support remains limited and partly indirect. Oral spironolactone keeps robust evidence as a non-antibiotic option for moderate-to-severe adult female acne. Topical spironolactone means a gel or cream applied to skin, rather than a daily pill. According to the 2026 narrative review in Clinical, Cosmetic and Investigational Dermatology, the topical form looks promising but lacks strong direct testing in adult women the full 2026 review.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the review found for pills versus creams
- Why the topical studies do not settle persistent acne
- What one gel trial did and did not show
- Where established options still stand
What the review found for pills versus creams
Oral spironolactone has consistent results for moderate-to-severe adult female acne. The review treats it as an established non-antibiotic choice for this group. The topical form does not have the same footing.
Studies were small, short-term, and varied in strength and design. That gap keeps daily care centered on proven options for now. The review positions topical use only for mild-to-moderate acne or when systemic treatment cannot be used. It also notes the United States has no standardized commercial formulation.
Why the topical studies do not settle persistent acne
Most topical trials enrolled few people, with none enrolling more than about 80 patients. Many tested 2-5% formulations for short periods. Many volunteers were men or mixed-sex groups, not adult women with persistent acne.
Results therefore transfer poorly to adult female care. Pooled analyses also mixed oral and topical results together. They were not restricted to adult women, which weakens their use for persistent cases.
What one gel trial did and did not show
A randomized trial tested 5% topical spironolactone gel twice daily. As reported by the Journal of Dermatological Treatment, total lesion count fell about 71% with active gel versus about 36% with vehicle the 2010 gel trial summary. The same trial found no significant effect on acne severity index.
Lesion counts improved while broader severity did not. That split matters for persistent acne. Fewer bumps help, but severity scores guide long-term plans. One small trial cannot support a switch in routine care.
Where established options still stand
The American Academy of Dermatology conditionally recommends oral spironolactone for acne. Its guidance does not list topical spironolactone as an established option. In contrast, clascoterone 1% cream received FDA approval as Winlevi in August 2020 for acne age 12 and older.
As reported by Medical Dialogues reporting FDA approval, approval followed two 12-week phase 3 trials in 1,440 patients the FDA approval notice. No trial has directly compared topical spironolactone with clascoterone. Readers should weigh these points with a dermatologist:.
- severity, duration, and prior response to benzoyl peroxide, retinoids, or oral therapy
- pregnancy plans, potassium issues, and reasons systemic therapy may be unsuitable
- access to compounding, cost, and how to track lesions and side effects for 8-12 weeks
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- The 2026 Review of Topical Antibiotic Monotherapy for Acne: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne